Intellipharmaceuticals International Inc.
IPCI
IPCI was delisted on the 20th of March, 2019.
24 hedge funds and large institutions have $1.16M invested in Intellipharmaceuticals International Inc. in 2017 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 1 closing their positions.
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
26% more funds holding
Funds holding: 19 → 24 (+5)
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
57% less capital invested
Capital invested by funds: $2.71M → $1.16M (-$1.55M)
89% less call options, than puts
Call options by funds: $30K | Put options by funds: $281K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FFA
First Foundation Advisors
Irvine,
California
|
+$161K |
| 2 |
ARTA
A.R.T. Advisors
New York
|
+$75.4K |
| 3 |
VAM
Verity Asset Management
Durham,
North Carolina
|
+$42.8K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$29.7K |
| 5 |
Morgan Stanley
New York
|
+$28.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$223K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$151K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$131K |
| 4 |
HFS
HL Financial Services
Louisville,
Kentucky
|
-$69K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.14K |
IPCI Hedge Fund Activity: Q3 2017 in Review
24 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Intellipharmaceuticals International Inc. (IPCI) for Q3 2017, worth a combined $1.16M — down 57% from $2.71M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new IPCI positions and 1 closed out — a net gain of 5 holders — while 6 added to existing stakes and 7 trimmed.
The largest buyer was First Foundation Advisors, adding an estimated $161K. The largest seller was Deutsche Bank, cutting an estimated $223K.
- 24 institutional investors held Intellipharmaceuticals International Inc. (IPCI) as of Q3 2017, up from 19 in Q2 2017.
- Funds reported $1.16M of Intellipharmaceuticals International Inc. stock for Q3 2017, down 57% quarter-over-quarter.
- 6 funds opened new Intellipharmaceuticals International Inc. positions in Q3 2017 and 1 closed out, a net change of +5 holders.
- The largest Intellipharmaceuticals International Inc. buyer in Q3 2017 was First Foundation Advisors, an estimated $161K added.
- The largest Intellipharmaceuticals International Inc. seller in Q3 2017 was Deutsche Bank, an estimated $223K sold.
Based on aggregated 13F filings for Q3 2017.